Kolkata, West Bengal -- (SBWIRE) -- 09/13/2013 -- Specialpennystockalert.com, an investment community with a special focus on updating investors with recent news on the U.S. stock market, issues news alert on Pandora Media Inc (NYSE:P), Weatherford International Ltd(NYSE:WFT), Boston Scientific Corporation (NYSE:BSX).
Pandora Media Inc (NYSE:P) shares increased 12.11% to $23.97. The company on Sept. 11 announced that the company's Board of Directors has appointed Brian McAndrews, formerly of Madrona Venture Group, Microsoft and aQuantive, to succeed Joe Kennedy as Chief Executive Officer, President and Chairman, effective immediately. In its search for a new CEO, the Board sought a candidate who could build on Pandora's leading position in internet radio and accelerate its fast-growing advertising business..
Should Investors Buy P After Yesterday’s Jump? Find Out Here
Weatherford International Ltd(NYSE:WFT) shares dropped 4.89% to $14.97. The company announced that it has scheduled a conference call for Tuesday, November 5, 2013 at 8:30 a.m. ET. The purpose of the conference call is to discuss results for the Company's third quarter ended September 30, 2013. The call will be open to the public.
Additionally, Equities research analysts at Cowen and Company increased their target price on shares of Weatherford from $19.00 to $20.00 in a research note issued to investors on August 1. The firm currently has an “outperform” rating on the stock.
How Should Investors Trade WFT After The Recent Volatility? Get Free Trend Analysis Here
Boston Scientific Corporation (NYSE:BSX) shares declined 0.08% to $11.91. In a significant milestone toward obtaining additional key regulatory approvals for the SYNERGY(TM)( )Stent System, Boston Scientific Corporation (NYSE: BSX) on Sept. 12 has completed enrollment in the EVOLVE II randomized, controlled clinical trial. The EVOLVE II trial is designed to further assess the safety and effectiveness of the SYNERGY Stent System and support U.S. Food and Drug Administration and Japanese regulatory approvals for the treatment of atherosclerotic coronary lesions.
Additionally, BSX’s stock was downgraded by stock analysts at CL King from a “buy” rating to a “neutral” rating in a report issued on Sept. 10. Separately, BSX’s stock has been upgraded by TheStreet Ratings from hold to buy on Sept. 2. The company's strengths can be seen in multiple areas, such as its compelling growth in net income, solid stock price performance, expanding profit margins, impressive record of earnings per share growth and largely solid financial position with reasonable debt levels by most measures.
Is BSX A Good Buy After The Recent Price Movement? Find Out Here
Specialpennystockalert.com is engaged in providing the most up to date and useful information on Microcap Stocks poised to breakout. Specialpennystockalert.com also provides investors with trend analysis, detailed company profiles, and most importantly a much needed "informational edge" which can be used as a tool for making investment decisions. To Receive Instant updates in the inbox, readers are advised to sign up for free at Specialpennystockalert.com.
The assembled information disseminated by Specialpennystockalert.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Specialpennystockalert.com does expect that investors will buy and sell securities based on information assembled and presented in phd-trading.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)